Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 14/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 2/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20874821 | 0.86 | MAPK1 (0.41) | MAPK1RIPK1CDK8 | |
| SCHEMBL2611061 | 0.85 | MAPK1 (0.55) | MAPK1RIPK1CDK8 | |
| SCHEMBL18237951 | 0.76 | ADORA2A (0.39) | MAPK1AXLCDK8NUDT1 | |
| SCHEMBL18237617 | 0.76 | ALDH1A1 (0.33) | MAPK1 | |
| Trifluoroacetic Acid SCHEMBL29699564 | 0.75 | CDK8 (0.34) | MAPK1CDK8 | |
| SCHEMBL29699518 | 0.75 | MAPK1 (0.48) | MAPK1RIPK1APPAXLCDK8 | |
| SCHEMBL10141177 | 0.75 | MAPK1 (0.48) | MAPK1RIPK1APPAXLNUDT1 | |
| SCHEMBL8047934 | 0.72 | KDM4E (0.36) | PRKCI | |
| SCHEMBL2967092 | 0.71 | MAPK1 (0.48) | MAPK1RIPK1APPAXLCDK8 | |
| SCHEMBL4569788 | 0.71 | AXL (0.41) | MAPK1APPAXLCDK8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295167-A1 | POTENT AND SELECTIVE INHIBITORS OF HER2 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230167133-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295167-A1 | POTENT AND SELECTIVE INHIBITORS OF HER2 | ERBB2, EGFR, ERBB3 | MAPK1 593/4885RIPK1 2842/4885APP 4400/4885 |
| US-20230167133-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | MAPK1 1046/4885RIPK1 465/4885APP 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.